Teglutik
E561110
Teglutik is an oral liquid formulation of the drug riluzole used to slow disease progression in patients with amyotrophic lateral sclerosis (ALS).
All labels observed (1)
| Label | Occurrences |
|---|---|
| Teglutik canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T6005041 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Teglutik Context triple: [Riluzole, hasBrandName, Teglutik]
-
A.
Tektitek
Tektitek is a Mayan language spoken primarily by the Tektiteko people in parts of Guatemala and Mexico.
-
B.
Trikka
Trikka (also known as Trikala) is an ancient city in Thessaly, Greece, traditionally regarded as the birthplace and principal cult center of the healing god Asclepius.
-
C.
Tuktukan
Tuktukan is a barangay (village-level administrative division) in the city of Taguig in Metro Manila, Philippines.
-
D.
Tegsedi
Tegsedi is an antisense oligonucleotide drug used to treat hereditary transthyretin-mediated amyloidosis by reducing the production of the transthyretin protein.
-
E.
Tikkana
Tikkana was a prominent 13th-century Telugu poet and scholar best known for translating a major portion of the Mahabharata into Telugu and helping shape classical Telugu literature.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Teglutik Target entity description: Teglutik is an oral liquid formulation of the drug riluzole used to slow disease progression in patients with amyotrophic lateral sclerosis (ALS).
-
A.
Tektitek
Tektitek is a Mayan language spoken primarily by the Tektiteko people in parts of Guatemala and Mexico.
-
B.
Trikka
Trikka (also known as Trikala) is an ancient city in Thessaly, Greece, traditionally regarded as the birthplace and principal cult center of the healing god Asclepius.
-
C.
Tuktukan
Tuktukan is a barangay (village-level administrative division) in the city of Taguig in Metro Manila, Philippines.
-
D.
Tegsedi
Tegsedi is an antisense oligonucleotide drug used to treat hereditary transthyretin-mediated amyloidosis by reducing the production of the transthyretin protein.
-
E.
Tikkana
Tikkana was a prominent 13th-century Telugu poet and scholar best known for translating a major portion of the Mahabharata into Telugu and helping shape classical Telugu literature.
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
brand name medication
ⓘ
pharmaceutical drug ⓘ |
| bioequivalence | bioequivalent to riluzole tablets in systemic exposure ⓘ |
| commonAdverseEffect |
abdominal pain
ⓘ
dizziness ⓘ elevated liver enzymes ⓘ fatigue ⓘ nausea ⓘ vomiting ⓘ |
| containsExcipient |
glycerol
ⓘ
sodium benzoate ⓘ sorbitol ⓘ |
| containsSubstance | riluzole ⓘ |
| contraindication | severe hepatic impairment ⓘ |
| dosingSchedule | twice daily ⓘ |
| drugInteraction |
CYP1A2 inducers
ⓘ
CYP1A2 inhibitors ⓘ |
| eliminationRoute | renal excretion of metabolites ⓘ |
| hasActiveIngredient | riluzole ⓘ |
| hasAdministrationDevice | oral dosing syringe ⓘ |
| hasAdvantage | facilitates dosing in patients with swallowing difficulties ⓘ |
| hasATCCode | N07XX02 ⓘ |
| hasDosageForm |
oral liquid
ⓘ
oral suspension ⓘ |
| hasStrength |
5 mg/mL
ⓘ
50 mg/10 mL ⓘ |
| indicatedFor | adult patients with amyotrophic lateral sclerosis ⓘ |
| mechanismOfAction |
blocks voltage-dependent sodium channels
ⓘ
inhibits glutamate release ⓘ interferes with excitatory neurotransmission ⓘ |
| metabolism | extensively metabolized in the liver ⓘ |
| overdoseEffect | may cause acute toxicity including neurologic symptoms ⓘ |
| pharmacologicalClass | glutamate release inhibitor ⓘ |
| pregnancyCategory | use only if potential benefit justifies potential risk ⓘ |
| primaryMetabolizingEnzyme | CYP1A2 ⓘ |
| regulatoryStatus | prescription only ⓘ |
| requiresMonitoring | liver function tests ⓘ |
| routeOfAdministration | oral ⓘ |
| storageCondition | store at controlled room temperature ⓘ |
| takenWith | water ⓘ |
| targetsDiseaseProcess | motor neuron degeneration in ALS ⓘ |
| therapeuticArea | neurology ⓘ |
| therapeuticEffect | slows disease progression in ALS ⓘ |
| treats |
ALS
ⓘ
amyotrophic lateral sclerosis ⓘ |
| usedAs | disease-modifying therapy in ALS ⓘ |
| warning | risk of liver injury ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Teglutik Description of subject: Teglutik is an oral liquid formulation of the drug riluzole used to slow disease progression in patients with amyotrophic lateral sclerosis (ALS).
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject linked to:
riluzole